SaaS vs Biotech 409A Valuation: Industry-Specific Differences

What is the difference between a SaaS and biotech 409A valuation?

The difference between a SaaS and biotech 409A valuation is methodology, not standard. A SaaS 409A leans on the market approach — revenue and ARR multiples from comparable public software companies — anchored to a recent priced round via the OPM backsolve. A biotech 409A, often pre-revenue for years, leans on probability-weighted methods that risk-adjust the value of clinical assets by phase-of-development success rates.

Both must satisfy the same IRS safe harbor and use a credentialed appraiser. What follows is a detailed look at how the approaches, comparables, discounts, and preparation differ between the two industries.

How methodology differs: revenue multiples vs probability-adjusted NPV

Every 409A appraiser must consider the income, market, and cost approaches and select the most appropriate one for the company's facts. The selection is where SaaS and biotech part ways. For a primer on the three approaches and how they are chosen, see our guide to the income, market, and cost approaches in 409A.

For SaaS, the market approach usually dominates. Recurring revenue and a deep set of public software comparables make EV/ARR and EV/Revenue multiples reliable indicators of enterprise value. As a SaaS company matures, the income approach (a discounted cash flow on its predictable subscription revenue) becomes a credible cross-check. Both are then connected to the common stock value through the OPM backsolve to the latest funding round.

For biotech, revenue multiples are usually irrelevant because there is no revenue. Instead, appraisers reach for a probability-adjusted net present value (rNPV) or a probability-weighted expected return method (PWERM). These methods forecast the cash flows a drug program could generate if approved, then weight those outcomes by the historical probability of clinical success at each phase and discount them at a high, risk-adjusted rate. The result reflects both the magnitude of a potential approval and the substantial risk that the asset never reaches market.

SaaS 409A valuation: the market approach dominates

A SaaS 409A valuation typically starts with the guideline public company method. The appraiser assembles a set of comparable publicly traded SaaS companies, derives their trading multiples (most often EV/ARR or EV/Revenue, sometimes EV/EBITDA for profitable peers), and adjusts those multiples for differences in growth rate, scale, gross margin, and net revenue retention before applying them to the subject company. Recurring revenue, low marginal cost, and predictable retention curves make this analysis robust.

That enterprise value is then reconciled with the company's most recent priced round through the option pricing model, which allocates total equity value across preferred and common classes and produces the common stock fair market value. For SaaS-specific mechanics — which multiples appraisers favor, how retention affects the analysis — see our dedicated guide to 409A valuation for SaaS companies.

Biotech 409A valuation: pre-revenue, milestone-driven

A biotech 409A valuation has to value a company whose worth lives almost entirely in its pipeline. A clinical-stage biotech may have years of negative cash flow ahead and a value that hinges on binary trial readouts. Appraisers respond with a probability-weighted framework: each program is valued as the risk-adjusted present value of its potential commercial cash flows, with phase-transition probabilities (Phase 1 to Phase 2, Phase 2 to Phase 3, Phase 3 to approval) applied to discount the optimistic scenario down to an expected value.

When a recent priced round exists, the OPM backsolve still anchors the total equity value, and the PWERM allocates that value across share classes and scenarios. The further a company is from its last round — common in biotech, where financings track clinical milestones — the more the appraiser must rely on the milestone-adjusted pipeline analysis rather than the backsolve alone. For the full pre-revenue methodology, see our guide to 409A valuation for biotech startups.

Comparison table: SaaS vs biotech 409A valuation

The table below summarizes how the core elements of a 409A valuation differ between a SaaS and a biotech company. Treat these as typical patterns; the appraiser's selection always depends on the specific facts.

Which valuation method is used for a pre-revenue biotech 409A?

A pre-revenue biotech 409A typically uses a probability-weighted expected return method (PWERM) or a risk-adjusted NPV, often anchored to the most recent priced round via an OPM backsolve. The appraiser models distinct exit and clinical scenarios, weights each by its probability of success, and discounts at a high risk-adjusted rate to reflect the binary nature of drug development.

In practice, the appraiser blends methods. The backsolve fixes total equity value at the round price; the PWERM allocates that value across scenarios and share classes, capturing the wide range of outcomes between trial failure and commercial approval. Where the last round is stale relative to a recent clinical readout, the milestone-adjusted analysis carries more weight. For the broader framework behind these choices, see our overview of 409A valuation methodology.

Do SaaS and biotech startups have different DLOMs?

Yes, biotech companies often carry a higher discount for lack of marketability (DLOM) than comparable-stage SaaS companies. The DLOM reflects how long and how uncertainly an investor must hold illiquid private stock before a liquidity event — and biotech's longer development timelines and binary clinical outcomes push that discount up relative to a SaaS company on a steadier revenue trajectory.

Mechanically, the DLOM is usually estimated with option-based models such as the protective put or the Finnerty model, both of which take volatility and expected holding period as inputs. Because biotech equity volatility and expected time to exit are typically higher, the resulting DLOM is larger, which lowers common stock value relative to preferred. SaaS DLOMs tend to compress faster as recurring revenue and a clearer exit path reduce both inputs.

Volatility and comparable company selection

Comparable selection is where industry expertise matters most. A SaaS appraiser builds a universe of public software companies and screens for growth rate, scale, gross margin, and retention to derive defensible revenue multiples. A biotech appraiser builds a universe of clinical-stage developers matched by therapeutic area, modality, and phase of development, then derives volatility and benchmark values from that peer set. Using the wrong comparable universe is one of the fastest ways to produce an indefensible report.

Volatility flows directly from the comparable set. Biotech comparables exhibit higher equity volatility because their stock prices swing on trial readouts and regulatory decisions; SaaS comparables are comparatively steadier. Since volatility is a central input to both the OPM allocation and the DLOM, the higher biotech figure systematically widens the gap between preferred and common stock value compared to a SaaS company at the same funding stage.

What founders in each industry should prepare

Giving the appraiser the right inputs upfront shortens turnaround and strengthens the report. The two industries need different document packages:

• SaaS founders: a current ARR/MRR breakdown, net and gross revenue retention, churn, growth history, gross margin, the cap table, and the most recent priced-round documents. A board-approved operating model helps support any income-approach cross-check.
• Biotech founders: the clinical development plan by program and phase, trial data and readouts to date, patent and IP position, the milestone and financing roadmap, any partnership or licensing terms, the cap table, and the most recent round documents.

In both cases, reconcile the cap table before the engagement begins — unrecorded SAFE conversions or option pool changes distort the OPM allocation regardless of industry. The cleaner the inputs, the more defensible the resulting common stock value.

Conclusion

The saas vs biotech 409a valuation comparison shows that industry, not just stage, dictates methodology. SaaS valuations rest on observable recurring revenue and software comparables; biotech valuations rest on the probability-weighted value of clinical assets and stage-matched peers. The volatility inputs, DLOMs, comparable universes, and document requirements all follow from that core difference — yet both must clear the same IRS safe harbor with a credentialed appraiser.

Whichever industry you are in, the defensibility of your 409A depends on using the right method and the right comparables for your business. Pick an appraiser who understands your sector, prepare the inputs the method needs, and the rest follows.